Abstract
Amyotrophic lateral sclerosis (ALS) is a debilitating and ultimately fatal indication that is the most prevalent adult-onset motoneuron disorder. ALS imparts tremendous suffering upon patients and caregivers alike. Exciting new insight has been obtained as to the etiology and initiation of the disease during the past decade, particularly affecting the larger, sporadic patient population. An important new discovery is the involvement of the TAR DNA binding protein (TDP-43) based upon genetic evidence and the presence of the cytosolic ubiquitinylated TDP-43 aggregates found during post-mortem analysis of damaged motoneuron in the spinal cord of ALS patients. Superoxide dismutase (SOD1) continues to be of interest for the ∼20% of the familial ALS patients who have the inherited form of the disease (∼15% of the total), but SOD1 does not appear to be as relevant as was once imagined for the sporadic patient population. We can now target specific biochemical pathways and deficits via traditional drug discovery efforts and may thus be able to achieve more effective therapeutic relief for patients who suffer from this disease. In this review we present a comprehensive discussion of current molecular targets and pathways that are of interest to small molecule drug discovery efforts for the treatment of ALS.
Keywords: Amyotrophic lateral sclerosis, ALS, neurodegeneration, heat shock, TDP-43, drug targets
Current Pharmaceutical Design
Title: Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis
Volume: 16 Issue: 18
Author(s): Aaron C. Pawlyk, Joel A. Cassel and Allen B. Reitz
Affiliation:
Keywords: Amyotrophic lateral sclerosis, ALS, neurodegeneration, heat shock, TDP-43, drug targets
Abstract: Amyotrophic lateral sclerosis (ALS) is a debilitating and ultimately fatal indication that is the most prevalent adult-onset motoneuron disorder. ALS imparts tremendous suffering upon patients and caregivers alike. Exciting new insight has been obtained as to the etiology and initiation of the disease during the past decade, particularly affecting the larger, sporadic patient population. An important new discovery is the involvement of the TAR DNA binding protein (TDP-43) based upon genetic evidence and the presence of the cytosolic ubiquitinylated TDP-43 aggregates found during post-mortem analysis of damaged motoneuron in the spinal cord of ALS patients. Superoxide dismutase (SOD1) continues to be of interest for the ∼20% of the familial ALS patients who have the inherited form of the disease (∼15% of the total), but SOD1 does not appear to be as relevant as was once imagined for the sporadic patient population. We can now target specific biochemical pathways and deficits via traditional drug discovery efforts and may thus be able to achieve more effective therapeutic relief for patients who suffer from this disease. In this review we present a comprehensive discussion of current molecular targets and pathways that are of interest to small molecule drug discovery efforts for the treatment of ALS.
Export Options
About this article
Cite this article as:
C. Pawlyk Aaron, A. Cassel Joel and B. Reitz Allen, Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis, Current Pharmaceutical Design 2010; 16 (18) . https://dx.doi.org/10.2174/138161210791293024
DOI https://dx.doi.org/10.2174/138161210791293024 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RNA Interference as a Tool for Alzheimers Disease Therapy
Mini-Reviews in Medicinal Chemistry Alzheimer's disease: Targeting the Cholinergic System
Current Neuropharmacology Conference Report: 10th International Summer School of Neurology: Celebrating a Decade of Success: 5th July, 2015 – 9th July, 2015 | Eforie Nord, Romania
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Regulation of Neuronal Cell Death and Neurodegeneration by Members of the Bcl-2 Family: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Are Catechins, Polyphenols in Tea, Good for Your Health?
Current Nutrition & Food Science Regulation of GABA Neurotransmission by Glutamic Acid Decarboxylase (GAD)
Current Pharmaceutical Design Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Linking New Paradigms in Protein Chemistry to Reversible Membrane-Protein Interactions
Current Protein & Peptide Science Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Genetics and Therapies for GM2 Gangliosidosis
Current Gene Therapy Docking of Natural Products against Neurodegenerative Diseases: General Concepts
Combinatorial Chemistry & High Throughput Screening Neurotoxicity: The Broad Framework of Electron Transfer, Oxidative Stress and Protection by Antioxidants
Current Medicinal Chemistry - Central Nervous System Agents Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Genetics of Congenital Heart Disease
Current Cardiology Reviews Modelling and Treating Amyotrophic Lateral Sclerosis through Induced- Pluripotent Stem Cells Technology
Current Stem Cell Research & Therapy Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology Non-Ceruloplasmin Copper Distinguishes A Distinct Subtype of Alzheimer’s Disease: A Study of EEG-Derived Brain Activity
Current Alzheimer Research